Literature DB >> 1834124

Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing.

Y P Keepers1, P E Pizao, G J Peters, J van Ark-Otte, B Winograd, H M Pinedo.   

Abstract

The sulforhodamine B (SRB) protein stain assay was compared with the tetrazolium (MTT) colorimetric assay for in vitro chemosensitivity testing of various human tumour cell lines. The SRB assay provided a better linearity with cell number and a higher sensitivity, and its staining was not cell-line dependent. In contrast to the MTT assay, the SRB assay stained recently lysed cells. Cell debris, however, was not stained by SRB and therefore the drug sensitivity data were not affected.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1834124     DOI: 10.1016/0277-5379(91)90142-z

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  80 in total

1.  Gompertzian growth pattern correlated with phenotypic organization of colon carcinoma, malignant glioma and non-small cell lung carcinoma cell lines.

Authors:  M A A Castro; F Klamt; V A Grieneisen; I Grivicich; J C F Moreira
Journal:  Cell Prolif       Date:  2003-04       Impact factor: 6.831

2.  The slow cell death response when screening chemotherapeutic agents.

Authors:  Joseph Blois; Adam Smith; Lee Josephson
Journal:  Cancer Chemother Pharmacol       Date:  2010-12-31       Impact factor: 3.333

3.  Amino acetate functionalized Schiff base organotin(IV) complexes as anticancer drugs: synthesis, structural characterization, and in vitro cytotoxicity studies.

Authors:  Tushar S Basu Baul; Smita Basu; Dick de Vos; Anthony Linden
Journal:  Invest New Drugs       Date:  2008-10-22       Impact factor: 3.850

4.  Transport and metabolism of some cationic ubiquinone antioxidants (MitoQn) in Caco-2 cell monolayers.

Authors:  Yan Li; J Paul Fawcett; Hu Zhang; Ian G Tucker
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2008 Oct-Dec       Impact factor: 2.441

5.  Tuning the cytotoxic properties of new ruthenium(III) and ruthenium(II) complexes with a modified bis(arylimino)pyridine Schiff base ligand using bidentate pyridine-based ligands.

Authors:  Ariadna Garza-Ortiz; Palanisamy Uma Maheswari; Martin Lutz; Maxime A Siegler; Jan Reedijk
Journal:  J Biol Inorg Chem       Date:  2014-01-16       Impact factor: 3.358

6.  Metabolism, mechanism of action and sensitivity profile of fluorocyclopentenylcytosine (RX-3117; TV-1360).

Authors:  Godefridus J Peters; Kees Smid; Leonardo Vecchi; Ietje Kathmann; Dzjemma Sarkisjan; Richard J Honeywell; Nienke Losekoot; Osnat Ohne; Aric Orbach; Eran Blaugrund; Lak Shin Jeong; Young Bok Lee; Chang-Ho Ahn; Deog Joong Kim
Journal:  Invest New Drugs       Date:  2013-09-19       Impact factor: 3.850

7.  Dibutyltin(IV) complexes containing arylazobenzoate ligands: chemistry, in vitro cytotoxic effects on human tumor cell lines and mode of interaction with some enzymes.

Authors:  Tushar S Basu Baul; Anup Paul; Lorenzo Pellerito; Michelangelo Scopelliti; Palwinder Singh; Pooja Verma; Andrew Duthie; Dick de Vos; Edward R T Tiekink
Journal:  Invest New Drugs       Date:  2009-12-11       Impact factor: 3.850

8.  Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines.

Authors:  L R Kelland; G Abel
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

9.  In vitro cytotoxic evaluation of novel dichlorodiorgano[N-(2-pyridylmethylene)arylamine]tin(IV) derivatives in human tumor cell lines.

Authors:  Tushar S Basu Baul; Dick de Vos
Journal:  Invest New Drugs       Date:  2009-08-27       Impact factor: 3.850

10.  Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines.

Authors:  A M Bergman; H M Pinedo; I Talianidis; G Veerman; W J P Loves; C L van der Wilt; G J Peters
Journal:  Br J Cancer       Date:  2003-06-16       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.